Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

We are very pleased to inform you that the following two trials have been closed after reaching their target accrual.

Canadian Cancer Trials Group IND.210 - A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients with Metastatic Colorectal Cancer - was
closed to accrual on February 12, 2015.

Canadian Cancer Trials Group IND.206 - A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours - was closed to accrual on February 5, 2015.

Thank you to all participating centres, staff and patients for contributing to the successful completion of these studies.